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CANNABINOID HYPEREMESIS SYNDROME
Cyclic vomiting syndrome: an important differential
diagnosis of cannabinoid hyperemesis syndrome
Tobias R Spiller resident 1, Katarina Künzler senior physician 2, Basil Caduff head 2
1Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland;
2Department of Internal Medicine, Limmattal Hospital, Urdorferstrasse 100, 8952 Schlieren, Switzerland
Chocron and colleagues discuss cannabinoid hyperemesis
syndrome.1 We would like to emphasise the importance of cyclic
vomiting syndrome (CVS) as a differential diagnosis, especially
in patients presenting to emergency departments. Such patients
require different pharmacological treatment from those with
cannabinoid hyperemesis syndrome.
Most patients with CVS present at emergency departments with
episodes of vomiting, nausea, and abdominal pain.2 These are
the same key symptoms as patients affected by cannabinoid
hyperemesis syndrome. Furthermore, up to one third of patients
with CVS are also recreational cannabis users.3 Thus, clinical
differentiation can be difficult, but the intensity of cannabis use
and the presence of a trigger for an episode of vomiting can be
diagnostic hints.
The Rome IV classification of functional gastrointestinal
disorders puts CVS and cannabinoid hyperemesis syndrome in
the same subgroup (B3): nausea and vomiting disorders.4 CVS
is defined as stereotypical episodes of vomiting with acute onset
enduring less than one week. Between episodes, vomiting must
be absent. To fulfil the diagnostic criteria of CVS, patients must
have had at least two such episodes in the past six months.3
The pathophysiology of CVS is complex and not fully
understood. It seems to be associated with migraine, including
similar genetic sequence variants in mitochondrial DNA. Most
episodes are associated with triggers (such as onset of menses,
infections, or psychological stress).2 There is often a family
history of migraine.
Evidence based treatment guidelines for CVS were published
recently.5 Abortive treatment for episodes includes triptans,
ondansetron, and in severe cases benzodiazepines. Prophylactic
treatment with tricyclic antidepressants or topimarate and
coenzyme Q10 is recommended in severe cases.
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